Houston, Texas, United States
As a Physician–Scientist and Medical Director in Infectious Diseases and Clinical Research, I bring more than 15 years of combined experience in clinical medicine, academic teaching, and pharmaceutical research leadership across Latin America. My background spans hospital-based infectious-disease care, global clinical trial oversight, and strategic medical affairs for high-impact therapeutic areas such as HIV, COVID-19, viral hepatitis, and vaccine development. At ICON plc, I provide medical and scientific oversight for Phase I–IV studies, ensuring protocol integrity, patient safety, and compliance with ICH-GCP, FDA, and EMA regulations. I collaborate with cross-functional teams in pharmacovigilance, biostatistics, data management, and regulatory strategy to deliver quality-driven outcomes. Previously at GlaxoSmithKline / ViiV Healthcare, I led regional HIV programs, developed medical-education strategies, managed investigator-initiated trials, and fostered KOL partnerships—earning multiple Global Employee Recognition Awards (2019–2023). Beyond clinical research, I am an educator and mentor, serving as Professor of Infectious Diseases at the Universidad Autónoma de San Luis Potosí since 2013. My academic interests integrate artificial intelligence, digital health, and epidemiology to advance precision medicine and global-health innovation. Recent continuing education includes Epidemiology for Health Systems (PAHO), Digital Health Series I (PAHO), and AI & Emerging Technologies (atingi). Authorized to work in the U.S. (Green Card Holder) — open to clinical research, medical affairs, data science, and infectious-disease innovation roles.
• Provide medical leadership for global clinical trials in infectious diseases and vaccines. • Review safety data, adverse-event narratives, and protocol deviations; support DSMB and regulatory submissions. • Ensure study compliance with ICH-GCP, FDA, and EMA standards. • Deliver therapeutic and protocol training for investigators and internal teams. • Contribute to ICON’s Infectious Diseases & Vaccines Collaboration Group, improving cross-regional processes and study quality.
Provide medical oversight for global clinical trials in infectious diseases and vaccines, ensuring compliance with ICH-GCP, FDA, and EMA standards. Review safety data, adverse event narratives, and protocol deviations; support safety reporting and DSMB data summaries. Collaborate with regulatory and pharmacovigilance teams on risk assessment, mitigation, and submission documentation. Deliver therapeutic and protocol training to investigators and internal stakeholders; contribute to site selection and feasibility strategy. Participate in ICON’s Infectious Diseases and Vaccines Collaboration Group to address regulatory and operational challenges across global sites.
• Delivered pre and post graduate training in Infectious diseases in general, HIV, and Semiology. • Designed and taught postgraduate courses in internal medicine and infectious diseases. • Mentor at IDSA Mentorship program - iDMentorship365
• Oversaw sponsor- and investigator-initiated HIV studies ensuring safety and data integrity. • Developed and executed regional medical strategies, publications, and KOL engagement plans. • Supported pharmacovigilance, HEOR, and medical-education initiatives aligned with global R&D goals. • Awarded annual Global Employee Recognition (2019–2023) for excellence in scientific collaboration.
Oversaw sponsor- and investigator-initiated studies in Mexico; ensured regulatory compliance, patient safety, and data integrity. Developed and executed medical strategies, publications, and KOL engagement plans aligned with global R&D priorities. Supported pharmacovigilance and risk-management programs, medical education, and budget oversight.
Provided specialized care in HIV, viral hepatitis, tuberculosis, and opportunistic infections in inpatient and outpatient settings. Designed and delivered academic courses in internal medicine and infectious diseases, mentored residents and research fellows. Led hospital infection-control initiatives and contributed to institutional antimicrobial stewardship programs.